ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,638.94
2.13%
US Tech 100
19,167.20
2.31%
다우존스 지수
41,488.19
1.65%
Bitcoin
84,231.16
-0.14%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Pieris Pharmaceuticals Inc (PIRS)

  7. Pieris Pharmaceuticals Inc (PIRS) 뉴스

PIRS

Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:PIRS
일자시간출처헤드라인심볼기업
2024/12/1709:44Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1709:44Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1709:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1709:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1709:42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1706:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1306:15Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/1306:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/0704:21Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/0322:30Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/12/0322:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/1906:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/1423:07Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/1406:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/1214:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/0723:01Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/0722:30GlobeNewswire Inc.Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic MalformationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/0707:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/11/0707:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/10/1721:00Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/10/1720:30GlobeNewswire Inc.Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial OfficerNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/10/1521:00Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/10/0321:00Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/10/0321:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/08/1505:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PIRSPieris Pharmaceuticals Inc
2024/08/1307:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/08/0905:17Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/08/0905:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/08/0803:16Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PIRSPieris Pharmaceuticals Inc
2024/08/0121:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PIRSPieris Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:PIRS

최근 히스토리

AMEX
XTN
SPDR S&P Transportation
BIT
F15595
Vontobel Financial Produ...
BIT
UB82CH
Unicredit Bank
BIT
UB22F5
UniCredit Bank
TSXV
NZRE.H
Net Zero Renewable Energy
USOTC
BZLYF
Beazley (PK)
BIT
UC7SQ5
Unicredit Bank
BIT
UC5CFM
Unicredit Bank
USOTC
CPPKF
Faraday Copper (QX)
NYSE
WPM
Wheaton Precious Metals
NYSE
PPG
PPG Industries
BIT
UB6DG1
Unicredit Bank
BIT
UC2BXJ
Unicredit Bank
NASDAQ
LNT
Alliant Energy
EU
XS2333391303
Royal Schiphol Group NV ...
BIT
UB22H3
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지